Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampin on the Pharmacokinetics of HS-10504 in Healthy Participants
NCT07770217Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Aug 2026
- Primary completion
- Sep 2026
01
Overview
Phase 1, open-label, single-arm trial of HS-10504, sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Observed Plasma Concentration at 192 hours, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration at 192 hours and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
HS-10504
Beyond the preview
Go deeper on NCT07770217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07770217.